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INTRODUCTION
Ampulla of Vater cancer accounts for approximately 6%
of the tumors occurring in the region of the head of the pan-
creas (1). The majority of tumors in this region are pancreatic
adenocarcinomas and the remainders are divided among bile
duct carcinomas, duodenal carcinomas, endocrine tumors and
metastatic lesions. Patients with cancer of the ampulla of
Vater account for up to 36% of those undergoing surgery
for pancreato-duodenal malignacies and are the only patients
among those affected by cancers of biliopancreatic origin who
have upto a 50% chance of being cured by surgery alone (2-9).
In addition, these tumors grow more slowly than cholangio-
carcinoma and pancreatic adenocarcinoma.
Ampulla of Vater cancer appears as a heterogenous disease
from the pathophysiological and molecular point of view.
They can arise as a feature of a familial cancer syndrome or
as a sporadic and quite uncommon event among gastroin-
testinal malignancies. In the latter case, they can rise from a
preexisting adenoma, closely resembling the colon adenoma-
carcinoma sequence. This group of ampullary neoplasm has
the histologic appearance of a tubular colon adenocarcinoma,
shows an expansive pattern of growth and is characterized by
a K-ras mutational rate similar to that of colon cancer (10).
The existence of these types of ampullary tumors, which
share some biological characteristics with colon carcinomas,
may partially explain their striking difference from pancre-
atic and biliary tract cancers in terms of growth behavior and
patient survival.
Cyclooxygenase (COX), also referred to as prostaglandin
endoperoxide synthase, is the rate-limiting enzyme for the
metabolic conversion of arachidonic acid to prostaglandins
(PGs) and related eicosanoids. There are at least two isoforms
of cyclooxygenase, COX-1 and COX-2. COX-1 is constitu-
tively expressed in many tissues and cell types (11), but in
some cases is increased during differentiation (12). By con-
trast, the expression of COX-2 is frequently up-regulated by
mitogens, cytokines and tumor promoters. 
Greater than 80% of colon cancers in humans have in-
creased COX-2 levels when compared to adjacent normal
tissue (11). The antitumor effect of COX-inhibitor (NSAIDs)
in colorectal tumorigenesis is evidenced by abundant data
from epidemiologic studies (12, 13), studies in patients with
familial adenomatous polyposis (FAP) (14, 15), and multi-
ple experiments in rodent models of colon cancer (16-19).
One potential mechanism for the antitumor effect of NSAIDs
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Expression of Cyclooxygenase-2 and Its Correlation with 
Clinicopathologic Factors of Ampulla of Vater Cancer
There has been no report for the expression of cyclooxygenase-2 (COX-2) and
its clinicopathologic and biologic significance in ampulla of Vater cancer. This
study was aimed for the clarification of COX-2 expression and its biologic roles
in ampulla of Vater cancer. Fourty-six patients with ampulla of Vater cancer were
enrolled and their COX-2 expression and clinicopathologic features were analyzed.
The median age of patients was 60 yr and the mean duration of follow-up was
35 months (range: 14-82 months). Immunohistochemical stainings for COX-2,
Ki-67, CD34 and TUNEL staining were performed. The immunoreactive COX-2
expression was present in 24 (52.2%) patients of ampulla of Vater cancer and
mainly localized in cytosolic and perinuclear region. There was no significant dif-
ference in the length of survival between COX-2 postive and negative group
(p=0.9420 by Log Rank test). Also, there were no significant differences of pro-
liferation index (p=0.326), apoptotic index (p=0.764) and microvessel density
(p=0.135) between COX-2 positive and negative group. Initial pTNM stage (p=
0.0028 by Log Rank test) and blood transfusion over 4 pints during operation
(p=0.0254 by Log Rank test) were independent prognostic factor in patients with
ampulla of Vater cancer. It is suggested that immunoreactivity of COX-2 is not
correlated with clinicopathologic and biologic features of ampulla of Vater cancer.
Key Words : Vater’s Ampulla; Duodenal Neoplasms; Prostaglandin-Endoperoxide Synthase; Ki-67
antigen; Apoptosis; Antigen CD34
Received : 26 August 2002
Accepted : 28 November 2002Expression of COX-2 in Ampulla of Vater Cancer 219
could involve inhibition of prostaglandin (PG) synthesis.
An important role for PGs in the pathogenesis of colon can-
cer has been suggested by several lines of evidence: (a) the
level of PGE2 (20) and the mRNA for COX-2 (21) are ele-
vated in human colon cancers; (b) PGs stimulate the prolif-
eration of colon cancer cells (22); (c) PGE2 may interfere
with host antitumor immunologic functions (23). Tsujii et
al. (24) have shown that NSAIDs can inhibit angiogenesis
by inhibiting COX-2 activity in colon carcinoma cells and
downregulating the production of angiogenic factors. Another
study has shown that NSAIDs could reduce the proliferation
of HT-29 colon cancer cells in vitro, and they caused cell
cycle quiescence and apoptosis, both of which could account
for their anti-proliferative effect (25).
To our knowledge, there has been no report for the expres-
sion of COX-2 in ampulla of Vater cancer. For the intestinal
type of ampulla of Vater cancer, which is the most common
among the ampullary cancers, an adenoma-carcinoma se-
quence, which is similar to colorectal cancer, has been pos-
tulated, and we hypothesized that biological study for COX-2
expression in ampulla of Vater cancer will demonstrate the
similar clinicopathological significance with that of colorec-
tal cancers. Hence, we have collected the surgical specimens
of ampulla of Vater cancer and executed the immunohisto-
chemical staining for COX-2, and correlated the results of
immunohistochemical staining with the clinicopathologic
parameters such as pTNM staging, cell type of tumor, in-
volvement of resection margin and patient’s survival.
PATIENTS AND METHODS 
Patients
Except for one case of postoperative mortal course (within
30 days) and 8 cases of short-term follow-up (less than 13
months), 46 patients of ampulla of Vater cancer who under-
went curative surgical resection between January 1995 and
August 2000 at our institution were included in our study.
The median age of patients was 60 yr (range: 36-76 yr), and
included 27 male (58.7%) and 19 female (41.3%) patients.
The mean duration of follow-up was 35 months (range: 14-
82 months). Twenty three (50%) patients were deceased
during the follow-up period and 23 (50%) patients were still
alive until the completion of follow-up.
Immunohistochemical Staining and Interpretation
The specimens obtained from surgical resection were fixed
in 10%-buffered formalin, processed routinely, and embedded
in paraffin. Five- m sections were stained with hematoxylin
and eosin, and histopathological diagnosis was confirmed by
at least two pathologists. In each case, accompanying normal
mucosa was collected for comparison.
Tissue immunohistochemical staining was done with LSAB
kit (DAKO, Carpinteria, CA, U.S.A.) with avidin-biotin
peroxidase complex method. The deparaffinized slide was
immersed for 45 min in 0.3% hydrogen peroxide in methanol
solution to deplete endogenous peroxide. Nonspecific bind-
ing sites were saturated with 0.3% bovine serum albumin
and normal goat serum diluted to 1:66.7 in PBS for 20 min.
After they were washed with PBS, separate sections were
incubated with primary antibodies against COX-2 (1  g/mL,
Santa Cruz, Arbington, U.K.), Ki-67 (Signet Laboratories,
Dedham, MA, U.S.A.) and CD34 (Immunotech, Marseille,
France) at dilution of 1:50 in a humidified chamber at room
temperature for 30 min. The sections were then washed with
PBS for 10 min. Biotinylated goat antirabbit IgG were applied
onto the tissue sections, and incubated at room temperature
for 30 min. After washing with PBS for 10 min, these tis-
sues were incubated with avidin-biotinylated peroxidase for
45 min. Finally, color was developed by the immersion of
the sections in a peroxidase substrate solution with aminoethyl
carbamazole. The sections were counterstained with Mayer’s
hematoxylin and were examined under light microscope.
For each tissue specimen, the presence or absence of stain-
ing with COX-2 was divided as positive or negative, and
the observer assessed all tissues on the slide to assign the
positive/negative status. Immunostaing for COX-2 appeared
to be localized in cytosolic and perinuclear region (Fig. 1).
For evaluation of proliferation index (PI), the area with a
high number of immunolabelled neoplastic nuclei were
chosen. Only distinctly immunoreactive tumor cell nuclei
were included, and the areas with necrosis and hemorrhage,
section borders and vascular endothelium were omitted. In
each specimen, approximately 1,000 tumor cells were counted
in high-power fields using an eye grid. PI was defined as the
ratio of labeled cells to total number of cells counted, repre-
sented in percentages.
The number of apoptotic bodies was determined and was
expressed in relation to the total number of cells within 20
random high-power fiels (area of each field 0.07 mm2). Strict
criteria were used to define a cell as apoptotic on the H&E
and TUNEL stained sections. These were: the presence of a
condensed and often fragmented nucleus together with a sur-
rounding halo. Cells containing weakly to moderately TUNEL
positive nuclei in the absence of these additional morpho-
logic features were not assessed as apoptotic. The apoptotic
index (AI) was calculated as the percentage of tumor cell
apoptotic bodies per total number of tumor cells counted
for each case. Microvessel density was determined as mean
number of CD34 positive microvessels in four ×200 fields.
Statistical Analysis
Comparison between the clinicopathological factors and
immunohistochemical staining was performed using the chi-
square test, Student t-test, one-way ANOVA and the linear220 H.J. Kim, T.S. Sohn, K.T. Lee, et al.
regression analysis. The survival time and the cumulative
survival rate were estimated using the Kaplan-Meier method.
The significance level was set at 5% for each analysis, and
the SPSS (version 10.0, SPSS Inc., U.S.A.) was used for sta-
tistical analysis.
RESULTS
Clinicopathologic Features of Patients with Ampulla
of Vater Cancer
No patient had a familiy history of malignant gastroin-
testinal disease, including familial adenomatous polyposis
(FAP) and hereditary non-polyposis colorectal cancer syn-
drome. The 1, 2, 3, 4, and 5 yr cumulative survival rates of
46 patients with ampulla of Vater cancer were 97.8%, 77.9%,
57.0%, 42.2% and 35.2%, respectively, and median and
mean survival were 39 and 48.9 months, respectively (Fig. 2).
Among 46 patients of ampullary cancer, 27 (58.7%) were
male and 19 (41.3%) were female. There was no significant
difference of cumulative survival rate between the group of
male and female patients.
Among 46 patients of ampullary cancer, twenty four
patients (52.2%) were pertained to pTNM stage II and fol-
lowed by stage III (15 patients, 32.6%), stage I (5 patients,
7.8%) and stage IV (2 patients, 3.1%). There was no signif-
icant difference in the distribution of pTNM stage with ref-
erence to the presence or absence of COX-2 immunostaining
(Table 1). However, there was significant difference of cumu-
lative survival rate between the groups of pTNM stage (Fig.
3). Subdividing the pTNM staging to pT and pN staging,
there were significant differences of cumulative survival rate
between the groups of pT and pN stage (Fig. 3).
Concerning the postoperative histopathology, well-differ-
entiated tumor was most frequent (23 patients, 50.0%), fol-
lowed by moderately differentiated (18 patients, 39.1%) and
poorly differentiated tumor (5 patients, 10.9%). There was
no significant difference in the distribution of tumor histo-
pathology with reference to the presence or absence of COX-2
immunostaining (Table 1). There was a different tendency of
cumulative survival rate between the groups of tumor histo-
patholgy, however, did not reach the statistical significance
(Fig. 3).
In our study, 31 patients (67.4%) of ampullary cancer had
lymphatic tumor emboli in postoperative histopathology.
There was no significant difference of the presence or absence
Fig. 1. Marked expression of immunoreactive COX-2 staining was
noticed mainly in cytosolic and perinuclear region of cancer cells
(×400).
Age (yr) (mean±SD) 60.4±9.5 56.3±7.1 NS 
Sex (M/F)  18/6  9/13  0.035
pTNM stage  NS
I 2  3 
II 11  13 
III 10  5 
IV 1 1
Differentiation NS
well differentiated  10  13
moderately differentiated  10  8 
poorly differentiated  4  1  NS
Complete resection (R0/R1)  24/0  22/0  NS
Lymphatic tumor emboli (+/-)  9/15  6/16  NS
COX-2 (+) COX-2 (-)
(n=24) (n=22) p-value
Table 1. Comparisons of clinicopathologic features between
COX-2 positive and negative group of patients with ampulla of
Vater cancer
NS: not significant.
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Fig. 2. The cumulative survival rate of 46 patients with ampulla of
Vater cancer. The median and mean survival were 39 and 48.9
months, respectively.
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of lymphatic tumor emboli with reference to the COX-2
immunostaining (Table 1). There was a different tendency
of cumulative survival rate between the positive and nega-
tive group of lymphatic tumor emboli, however, did not reach
the statistical significance (Fig. 3).
Among 46 patients of ampullary caner, 9 patients (19.6%)
had more than 4 pints of blood transfusion during the oper-
ation. There was significant difference of cumulative survival
rate between the group of patients whether they had received
more than 4 pints of blood transfusion or not (Fig. 3).
Immunohistochemical Staining of COX-2 and its Cor-
relation with Proliferation Index (PI), Apoptotic Index
(AI) and Microvessel Density
In the tissues of ampulla of Vater cancer, we found marked
expression of immuno-reactive COX-2 in inflammatory
mononuclear cells, vascular endothelial cells and cancer cells
(Fig. 1). The cytosolic and perinuclear immunostaining for
COX-2 was appeared in 24 (52.2%) patients with ampulla
of Vater cancer. There was no significant difference of cumu-
lative survival rate between the COX-2 positive and COX-
2 negative group (p=0.9420 by Log Rank test, Fig. 4).
There were no significant differences of PI (p=0.326), AI
(p=0.764), and microvessel density (p=0.135) in reference
to the presence or absence of COX-2 immunostaining (Fig.
5). Also, there were no impacts on survival for PI, AI, and
microvessel density in patients with ampulla of Vater cancer.
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Fig. 3. The comparisons of cumulative survival rate between the groups of pTNM stage, tumor histopathology, lymphatic tumor emboli,
and blood transfusion.
C
u
m
u
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
1.2
1.0
0.8
0.6
0.4
0.2
0.0
10 20 30 40 50 60 70 80 90
Survival (Months)
censored
poor differentiated
mod differentiated
censored
censored
well differentiated
C
u
m
u
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
1.2
1.0
0.8
0.6
0.4
0.2
0.0
10 20 30 40 50 60 70 80 90
Survival (Months)
p=0.0738 by Log Rank test
p=0.0652 by Log Rank test lymph invasion(+)
censored
censored
lymph invasion(-)
C
u
m
u
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
1.2
1.0
0.8
0.6
0.4
0.2
0.0
10 20 30 40 50 60 70 80 90
Survival (Months)
p=0.0254 by Log Rank test transfusion > 4 pints
censored
censored
transfusion < 4 pints
C
u
m
u
l
a
t
i
v
e
 
S
u
r
v
i
v
a
l
1.2
1.0
0.8
0.6
0.4
0.2
10 20 30 40 50 60 70 80 90
Survival (Months)
Fig. 4. The comparison of cumulative survival rate between COX-2
positive and negative group of patients with ampulla of Vater can-
cer.
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DISCUSSION 
COX-2, a key enzyme required for the conversion of arachi-
donic acid to prostaglandins, plays an important role in the
promotion of intestinal tumorigenesis in animal models, but
the underlying mechanism of action is still poorly understood.
Eberhart et al. (22) have reported that COX-2 expression is
clearly up-regulated in the majority of colorectal carcinoma
compared with levels of expression in accompanying normal
mucosa. More recently, a subset of colorectal adenomas, the
precursor lesions in colorectal carcinogenesis, show up-regu-
lation of COX-2 mRNA.
Recently, several epidemiologic studies have suggested that
NSAIDs decrease the incidence of colorectal cancer (12, 13).
COX and PGs may play a role in this mechanism because
the main function of NSAIDs is in the inhibition of COX-1
and COX-2 enzymatic activity. Shiff et al. (26) reported that
NSAIDS could inhibit the proliferation, alter morphological
appearance, modify the cell cycle phase distribution and induce
cell death by apoptosis of HT-29 colon adenocarcinoma cells.
There have been several immunocytochemical studies in
localization of COX in the gastrointestinal tracts. The immu-
nolocalization of COX in normal human colon and colorec-
tal caner were reported by Mikkelson et al. (27) and Sano et
al. (28), respectively. They detected the expression of immu-
noreactive COX-2 in colorectal cancer cells, inflammatory
mononuclear cells, vascular endothelial cells, and fibroblasts,
but, immunoreactive COX-1 was very weak. In normal colonic
tissues, immunoreactive COX-1 and -2 were weakly expressed
in mucosal epithelial cells and vascular endothelial cells. In
our study for ampulla of Vater cancer, the result is similar,
and immunoreactive COX-2 staining was mainly localized
in cytosolic and perinuclear region of cancer cells.
Kokawa et al. (29) have reported that marked COX-2 ex-
pression was observed in 57% of pancreatic ductal adenocar-
cinomas, 58% of adenomas, and in 70% of adenocarcinomas
of intraductal pancreatic mucinous tumors (IPMTs) (38).
Likewise, COX-2 expression is known to be increased in
human gastric cancers (30) and esophageal cancers (31). Over-
expression of COX-2 in malignancies does not, however, seem
to be a general phenomenon, since COX-2 protein was not
found in human breast carcinoma (32).
In the current study, we found that immunoreactive COX-2
expression was noticed in 52.2% of patients with ampulla of
Vater cancer. To our knowledge, there has been no report with
a large number of patients with ampulla of Vater cancer focus-
ing on COX-2 expression and its correlation with clinico-
pathologic features. We found no significant difference in
the cumulative survival rate between COX-2 positive and
negative group, which was controversial points in previous
reports for COX-2 and its relation with survival (33-37).
Also, we have correlated the COX-2 expression with prolif-
erative index (PI), apoptotic index (AI), and microvessel
density of ampulla of Vater cancer and could not find sig-
nificant correlation between them. Our results of no correla-
tion between COX-2 and proliferation, apoptosis, and angio-
genesis for ampullary cancer were contradictory to the pre-
vious report.
Cao et al. (38) have reviewed the many actions of COX-2
in cellular dynamics and in cancer. They indicate that the
prostaglandin products of the COX-2 pathway enhance cell
proliferation and growth in both normal and tumor cells.
Other important actions of COX-2 on cellular process which
they reviewed, are inhibition of apoptosis, promotion of tumor
cell migration, cell adhesion, tumor invasiveness and role of
tumor angiogenesis. So far, it is not certain whether or not the
dissension is due to the peculiar biologic properties of ampul-
la of Vater cancer. Also, it is not certain whether or not the
relatively small number of cases included in our study is the
probable cause of statistical insignificance. Clinical studies
of prospective design with a large number of samples for
elucidating the biologic and therapeutic role of COX-2 in
ampulla of Vater cancer will be warranted.
In our study, initial pTNM stage and blood transfusion
Fig. 5. The comparisons of PI, AI, and microvessel density between the COX-2 positive and negative group of patients with ampulla
of Vater cancer. Each data contains median, quartiles and extreme values.
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more than 4 pints during operation were independent prog-
nostic factors for patients with ampulla of Vater cancer. Al-
though lymphatic tumor emboli and tumor differentiation
in postoperative histopathology appeared as statistically in-
significant prognostic factors, they showed distinctively dis-
crepant tendency of survival.
In conclusion, our study suggests that COX-2 expression
in ampulla of Vater cancer is not correlated with the clinico-
pathologic and biologic features of tumor, such as length of
survival, proliferation, apoptosis and angiogenesis of tumor
cells.
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